国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 2024年度持续督导跟踪报告 国泰海通证券股份有限公司（以下简称"保荐机构"）作为上海奥浦迈生物科技股 份有限公司（以下简称"奥浦迈"或"公司"）持续督导工作的保荐机构，根据《证券发 行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所 上市公司自律监管指引第 11 号——持续督导》等有关法律法规的规定，负责奥浦迈上 市后的持续督导工作，并出具本持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 发现以下情形之一的，应当督促上市公司做出说明并限期 | 上市公司未发生前述情况 | | | 改正，同时向上海证券交易所报告：（一）上市公司涉嫌 | | | | 违反《上海证券交易所股票上市规则》等上海证券交易所 | | | | 业务规则；（二）中介机构及其签名人员出具的专业意见 | | | 14 | 可能存在虚假记载、误导性陈述或重大遗漏等违法违规情 | | | | 形或其他不当情形；（三）上市公司出现《证券发行上市 | | | | 保荐业务管理办法》第七十一条、第七十二 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-036 上海奥浦迈生物科技股份有限公司 关于 2025 年第一季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上海证券交易所科创板股票上市规则》《企业会计准则》等相关法律 法规的规定，为真实、准确、公允的反映上海奥浦迈生物科技股份有限公司（以 下简称"奥浦迈"或"公司"）2025年第一季度的财务状况及经营情况，基于谨 慎性原则，公司对合并报表范围内截至2025年3月31日的各类资产进行减值测试， 对存在减值迹象的有关资产计提了减值准备。现将相关情况公告如下： 一、计提资产减值准备的情况概述 公司2025年第一季度拟计提信用减值损失和资产减值损失共计421.74万元， 具体情况如下表： 单位：万元 币种：人民币 | | 项目 | 2025年第一季度预计计提金额 | | --- | --- | --- | | 信用减值损失 | 应收账款坏账损失 | 304.01 | | 资产减值损失 | 存货跌价损失 | 117.73 | | | ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-037 上海奥浦迈生物科技股份有限公司 关于筹划重大资产重组事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次交易基本情况 上海奥浦迈生物科技股份有限公司（以下简称"公司"）拟通过发行股份及 支付现金的方式购买澎立生物医药技术（上海）股份有限公司100%股权，并募 集配套资金（以下简称"本次交易"）。本次交易预计达到《上市公司重大资产 重组管理办法》规定的重大资产重组标准。本次交易完成前后，公司的控股股东、 实际控制人不会发生变更，本次交易不构成重组上市。 二、本次交易进展情况 经分别向上海证券交易所申请，公司股票（证券简称：奥浦迈，证券代码： 688293）自2025年1月17日（星期五）开市起停牌，并于2025年1月24日（星期五） 开市起继续停牌，具体内容详见公司分别于2025年1月17日、2025年1月24日刊载 于上海证券交易所网站的《关于筹划重大资产重组事项的停牌公告》《关于筹划 重大资产重组事项进展并继续停牌的公告》。 202 ...

优化，成就与众不同 Optimization Makes Differences 证券代码：688293 证券简称：奥浦迈 二〇二五年五月 1 上海奥浦迈生物科技股份有限公司 2024 年年度股东大会 会议资料 | 2024 | 年年度股东大会会议须知 3 | | --- | --- | | 2024 | 年年度股东大会会议议程 6 | | 议案 1： | 8 | | 《关于公司<2024 | 年年度报告及其摘要>的议案》 8 | | 议案 2： | 9 | | 《关于公司<2024 | 年度财务决算报告>的议案》 9 | | 议案 3： | 12 | | 《关于公司<2024 | 年度董事会工作报告>的议案》 12 | | 议案 4： | 13 | | 《关于公司<2024 | 年度监事会工作报告>的议案》 13 | | 议案 5： | 14 | | 《关于公司<2024 | 年度独立董事述职报告>的议案》 14 | | 议案 6： | 15 | | 《关于公司 2025 | 年度董事薪酬的议案》 15 | | 议案 7： | 16 | | 《关于公司 2025 | 年度监事薪酬的议案》 16 | | 议案 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-035 上海奥浦迈生物科技股份有限公司 第二届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届监事会第八次会议于2025年4月28日通过通讯会议的方式召开。本次会议通知 及相关资料已于2025年4月21日送达全体监事。本次会议由监事会主席梁欠欠女 士召集并主持，会议应出席监事3名，实际出席监事3名，本次会议的召集、召开 方式符合相关法律、行政法规、部门规章、规范性文件和《公司章程》的规定， 会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，形成的会议决议如下： 1、审议通过了《关于公司<2025年第一季度报告>的议案》 监事会对公司2025年第一季度报告进行审核并发表书面意见，监事会认为： （1）公司严格按照各项法律法规、规章制度等的要求规范运作，公司2025 年第一季度报告的编制和审议程序符合相关法律法规、《公司章程》和公司内部 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-034 上海奥浦迈生物科技股份有限公司 第二届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届董事会第九次会议于2025年4月28日通过通讯会议的方式召开。本次会议通知 及相关资料已于2025年4月21日送达全体董事。本次会议由董事长肖志华先生召 集并主持，会议应出席董事7名，实际出席董事7名，本次会议的召集、召开方式 符合相关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，会议 决议合法有效。 二、董事会会议审议情况 经与会董事审议表决，形成的会议决议如下： 1、审议通过了《关于公司<2025年第一季度报告>的议案》 董事会对公司2025年第一季度报告进行审核并发表书面意见，董事会认为： （1）公司严格按照各项法律法规、规章制度等的要求规范运作，公司2025 年第一季度报告的编制和审议程序符合相关法律法规、《公司章程》和公司内部 管 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥83,678,844.28, representing a 4.98% increase compared to ¥79,706,760.24 in the same period last year[5] - Net profit attributable to shareholders decreased by 25.08% to ¥14,668,012.82 from ¥19,578,569.83 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 33.06% to ¥10,799,748.66 compared to ¥16,133,022.74 in the previous year[5] - The company reported a basic earnings per share of ¥0.13 for Q1 2025, down from ¥0.17 in Q1 2024[26] - Total revenue for Q1 2025 reached ¥83,678,844.28, a 4.0% increase from ¥79,706,760.24 in Q1 2024[25] - Net profit for Q1 2025 was ¥14,550,763.03, a decrease of 25.0% compared to ¥19,403,531.33 in Q1 2024[26] - Total operating costs increased to ¥62,185,716.32 in Q1 2025, up 5.0% from ¥58,919,501.84 in Q1 2024[25] - Operating profit for Q1 2025 was ¥22,473,249.81, slightly down from ¥23,105,634.60 in Q1 2024[25] - The total comprehensive income for Q1 2025 was ¥14,543,974.63, a decrease from ¥19,414,232.69 in Q1 2024[26] Cash Flow and Assets - The net cash flow from operating activities significantly improved to ¥43,308,029.62, a 665.63% increase from ¥5,656,507.94 in the same period last year[5] - The company's customer payment amount increased significantly by 47.73% compared to the same period last year, reflecting improved cash flow and collection efficiency[18] - The total current assets as of March 31, 2025, amounted to CNY 1,609,371,269.94, an increase from CNY 1,549,076,630.82 as of December 31, 2024[21] - The company's cash and cash equivalents as of March 31, 2025, were CNY 737,059,898.05, down from CNY 891,143,542.80 as of December 31, 2024[21] - Cash flow from operating activities for Q1 2025 was ¥43,308,029.62, significantly higher than ¥5,656,507.94 in Q1 2024[28] Research and Development - Research and development expenses totaled ¥12,114,331.01, marking a 56.51% increase from ¥7,740,448.49 year-on-year, accounting for 14.48% of operating revenue[5] - Research and development expenses increased to ¥12,114,331.01 in Q1 2025, up from ¥7,740,448.49 in Q1 2024, reflecting a focus on innovation[25] Investment and Market Position - The company reported a significant increase in investment income by 204.88% due to the maturity of several financial products in Q1 2025[8] - The company experienced a 53.73% increase in credit impairment losses, attributed to macroeconomic fluctuations and changes in customer conditions[8] - The company maintains a strong market position in cell culture products, which are expected to continue driving revenue growth due to sustained market demand[14] - CDMO service revenue increased by 27.11% compared to the previous year, indicating strong performance despite market challenges[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 3,027[10] - The largest shareholder, Xiao Zhihua, holds 24.90% of the shares, while the top ten shareholders collectively hold significant stakes[10] - The actual controllers of the company are Xiao Zhihua and He Yunfen, who together control 32.06% of the shares[12] Operational Developments - The company implemented a share buyback program in Q4 2024, which concluded in October 2024, resulting in no further buybacks in Q1 2025[8] - The company’s wholly-owned subsidiary, Aopumai Biotechnology (Taicang) Co., Ltd., officially commenced operations, focusing on the research and production of agarose products[18] - The company’s U.S. subsidiary's laboratory has been officially put into use, focusing on the development of culture media to support market expansion in the U.S.[19] - The company successfully passed the ISO 9001:2015 quality management system audit with "0 corrective actions," enhancing its market competitiveness[19] - The company is expected to receive the Qualified Person (QP) compliance statement in the second quarter, which will facilitate its entry into the EU market[19] Asset and Liability Overview - Total assets at the end of the reporting period were ¥2,307,695,080.00, a 0.94% increase from ¥2,286,250,982.16 at the end of the previous year[5] - The company’s total liabilities as of March 31, 2025, were CNY 196,632,223.68, up from CNY 190,970,352.87 as of December 31, 2024[23] - The company’s total assets reached CNY 2,307,695,080.00 as of March 31, 2025, compared to CNY 2,286,250,982.16 as of December 31, 2024[23]

Investment Rating - The report maintains a "Recommended" rating for the company [1][7][11] Core Insights - The company's revenue for 2024 is projected to be 297 million yuan, representing a year-over-year growth of 22.3%, while the net profit is expected to decline to 21 million yuan, a decrease of 61.0% [3][5][9] - The core business of cell culture media is experiencing strong growth, with a revenue increase of 27.51% in the second half of 2024, contributing 1.21 billion yuan to the total revenue [4][5] - The CDMO (Contract Development and Manufacturing Organization) business is underperforming, with a significant drop in gross margin due to increased depreciation from new capacity coming online [4][5] Financial Performance Summary - The company achieved a total revenue of 2.97 billion yuan in 2024, with a net profit of 0.21 billion yuan, reflecting a significant decline in profitability [3][4] - The gross margin for the core cell culture media business is 69.64%, while the CDMO segment reported a negative gross margin of -37.71% [4][5] - The company is involved in 247 R&D pipelines, with 29 in Phase 3 clinical trials and 8 in commercialization, indicating a robust pipeline for future growth [5][7] Future Projections - Revenue is expected to grow to 392 million yuan in 2025 and 510 million yuan in 2026, with net profits projected at 65 million yuan and 92 million yuan respectively [5][9] - The report adjusts profit forecasts for 2025-2027, with net profits expected to be 0.65 billion yuan in 2025, 0.92 billion yuan in 2026, and 1.26 billion yuan in 2027 [7][9] Market Position and Strategy - The company is actively expanding its market presence through both domestic and international channels, with overseas revenue growing by 98.06% in the second half of 2024 [4][5] - The report highlights the importance of the cell culture media business in the drug development lifecycle, suggesting a long-term growth trajectory as drug production scales up [5][7]

核心培养基业务收入快速增长。2024年公司产品业务实现收入2.4亿元(+42%)，其中CHO培养基实现收 入2亿元(+49%)；海外业务实现收入9446万元，同比+144%。2024 年销售毛利率为53%，同比-5.8pp， 预计主要系CDMO 业务的固定成本摊销。费用率方面，销售费用率8.5%(+1.8pp)， 管理费用率27.1% (+3.2pp)，研发费用率11.5%(-6.2pp)。2024 年公司计提资产减值损失954万元，计提信用减值损失692 万 元。此外，由于公司高新技术企业资格取消致使税率提升，2024 年所得税费用增加656 万元。 盈利预测与投资建议。预计公司2025-2027 年收入分别为4亿元、5.3 亿元、7亿元，公司储备药企项目 丰富，未来抗体商业化生产订单将驱动业绩增长，建议关注。 事件：公司发布 2024年报，2024年实现收入3亿元(+22.3%)，归母净利润2105万元(-61%)，扣非净利润 658.6 万元(-81%)。 风险提示：产品出海不及预期风险、创新药行业投融资不及预期风险、市场竞争风险。 培养基业务持续放量，产品管线数量突破性增长。2024 年使用公司培养基 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [4][20] Core Views - The company's product business revenue grew by 42% year-on-year, but net profit is under short-term pressure, with a projected revenue of 297 million yuan (+22.3%) and a net profit of 21 million yuan (-61.0%) for 2024 [1][7] - The decline in net profit is attributed to the operational costs associated with the new CDMO biopharmaceutical commercialization production platform and impairment losses of 10.03 million yuan [1][7] - The company has a strong pipeline with 247 confirmed drug development lines using its cell culture products, an increase of 77 from the previous year [2][16] Financial Performance - For 2024, the company achieved product sales of 244 million yuan (+42.0%) with a gross margin of 70.0% [1][7] - CDMO services generated revenue of 52.56 million yuan (-25.7%), primarily due to uncertainties in the biopharmaceutical industry affecting client financing [1][7] - The quarterly sales for 2024 are projected to improve sequentially: 8.05 million yuan in Q1, 11.62 million yuan in Q2, 15.84 million yuan in Q3, and 17.05 million yuan in Q4 [1][7] Regional Performance - The company's overseas business showed strong growth, with foreign revenue increasing by 144.0% compared to the previous year [2][7] Earnings Forecast - The earnings forecast has been adjusted, with expected net profits of 78 million yuan and 112 million yuan for 2025 and 2026, respectively, and a new projection of 153 million yuan for 2027 [2][20] - The current price-to-earnings (PE) ratios are projected at 58x for 2025, 41x for 2026, and 30x for 2027 [2][20] Key Financial Metrics - The company reported a net profit margin of 1.0% for 2024, with a significant increase expected in subsequent years [3][23] - The projected revenue growth rates are 27.1% for 2025 and 21.3% for 2026, indicating a recovery trend [3][23]